Global Oligonucleotide Therapy Based Drug Market Research Report 2025(Status and Outlook)
Description
Report Overview
Oligonucleotides can be used to modulate gene expression via a range of processes including RNAi, target degradation by RNase H-mediated cleavage, splicing modulation, non-coding RNA inhibition, gene activation and programmed gene editing.
The global Oligonucleotide Therapy Based Drug market size was estimated at USD 12900.0 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 3.70% during the forecast period.
This report provides a deep insight into the global Oligonucleotide Therapy Based Drug market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Oligonucleotide Therapy Based Drug Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Oligonucleotide Therapy Based Drug market in any manner.
Global Oligonucleotide Therapy Based Drug Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Sarepta Therapeutics_x000D_
Ionis Pharmaceuticals_x000D_
Alnylam_x000D_
Biogen_x000D_
Nippon Shinyaku_x000D_
Sobi_x000D_
Novartis_x000D_
BioNTech_x000D_
Pfizer_x000D_
Moderna Therapeutics_x000D_
Jazz Pharmaceuticals_x000D_
CureVac_x000D_
Regulus Therapeutics_x000D_
ProQR_x000D_
Secarna_x000D_
MiNA Therapeutics_x000D_
Sylentis_x000D_
Arrowhead_x000D_
Silence Therapeutics_x000D_
Dicerna
Market Segmentation (by Type)
Antisense Oligonucleotides (ASO)_x000D_
siRNA_x000D_
mRNA
Market Segmentation (by Application)
Neuromuscular Diseases_x000D_
hATTR_x000D_
COVID-19_x000D_
Other
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Oligonucleotide Therapy Based Drug Market
Overview of the regional outlook of the Oligonucleotide Therapy Based Drug Market:
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Oligonucleotide Therapy Based Drug Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Oligonucleotide Therapy Based Drug, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
Oligonucleotides can be used to modulate gene expression via a range of processes including RNAi, target degradation by RNase H-mediated cleavage, splicing modulation, non-coding RNA inhibition, gene activation and programmed gene editing.
The global Oligonucleotide Therapy Based Drug market size was estimated at USD 12900.0 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 3.70% during the forecast period.
This report provides a deep insight into the global Oligonucleotide Therapy Based Drug market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Oligonucleotide Therapy Based Drug Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Oligonucleotide Therapy Based Drug market in any manner.
Global Oligonucleotide Therapy Based Drug Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Sarepta Therapeutics_x000D_
Ionis Pharmaceuticals_x000D_
Alnylam_x000D_
Biogen_x000D_
Nippon Shinyaku_x000D_
Sobi_x000D_
Novartis_x000D_
BioNTech_x000D_
Pfizer_x000D_
Moderna Therapeutics_x000D_
Jazz Pharmaceuticals_x000D_
CureVac_x000D_
Regulus Therapeutics_x000D_
ProQR_x000D_
Secarna_x000D_
MiNA Therapeutics_x000D_
Sylentis_x000D_
Arrowhead_x000D_
Silence Therapeutics_x000D_
Dicerna
Market Segmentation (by Type)
Antisense Oligonucleotides (ASO)_x000D_
siRNA_x000D_
mRNA
Market Segmentation (by Application)
Neuromuscular Diseases_x000D_
hATTR_x000D_
COVID-19_x000D_
Other
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Oligonucleotide Therapy Based Drug Market
Overview of the regional outlook of the Oligonucleotide Therapy Based Drug Market:
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Oligonucleotide Therapy Based Drug Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Oligonucleotide Therapy Based Drug, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
Table of Contents
175 Pages
- 1 Research Methodology and Statistical Scope
- 1.1 Market Definition and Statistical Scope of Oligonucleotide Therapy Based Drug
- 1.2 Key Market Segments
- 1.2.1 Oligonucleotide Therapy Based Drug Segment by Type
- 1.2.2 Oligonucleotide Therapy Based Drug Segment by Application
- 1.3 Methodology & Sources of Information
- 1.3.1 Research Methodology
- 1.3.2 Research Process
- 1.3.3 Market Breakdown and Data Triangulation
- 1.3.4 Base Year
- 1.3.5 Report Assumptions & Caveats
- 2 Oligonucleotide Therapy Based Drug Market Overview
- 2.1 Global Market Overview
- 2.1.1 Global Oligonucleotide Therapy Based Drug Market Size (M USD) Estimates and Forecasts (2020-2033)
- 2.1.2 Global Oligonucleotide Therapy Based Drug Sales Estimates and Forecasts (2020-2033)
- 2.2 Market Segment Executive Summary
- 2.3 Global Market Size by Region
- 3 Oligonucleotide Therapy Based Drug Market Competitive Landscape
- 3.1 Company Assessment Quadrant
- 3.2 Global Oligonucleotide Therapy Based Drug Product Life Cycle
- 3.3 Global Oligonucleotide Therapy Based Drug Sales by Manufacturers (2020-2025)
- 3.4 Global Oligonucleotide Therapy Based Drug Revenue Market Share by Manufacturers (2020-2025)
- 3.5 Oligonucleotide Therapy Based Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.6 Global Oligonucleotide Therapy Based Drug Average Price by Manufacturers (2020-2025)
- 3.7 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
- 3.8 Oligonucleotide Therapy Based Drug Market Competitive Situation and Trends
- 3.8.1 Oligonucleotide Therapy Based Drug Market Concentration Rate
- 3.8.2 Global 5 and 10 Largest Oligonucleotide Therapy Based Drug Players Market Share by Revenue
- 3.8.3 Mergers & Acquisitions, Expansion
- 4 Oligonucleotide Therapy Based Drug Industry Chain Analysis
- 4.1 Oligonucleotide Therapy Based Drug Industry Chain Analysis
- 4.2 Market Overview of Key Raw Materials
- 4.3 Midstream Market Analysis
- 4.4 Downstream Customer Analysis
- 5 The Development and Dynamics of Oligonucleotide Therapy Based Drug Market
- 5.1 Key Development Trends
- 5.2 Driving Factors
- 5.3 Market Challenges
- 5.4 Industry News
- 5.4.1 New Product Developments
- 5.4.2 Mergers & Acquisitions
- 5.4.3 Expansions
- 5.4.4 Collaboration/Supply Contracts
- 5.5 PEST Analysis
- 5.5.1 Industry Policies Analysis
- 5.5.2 Economic Environment Analysis
- 5.5.3 Social Environment Analysis
- 5.5.4 Technological Environment Analysis
- 5.6 Global Oligonucleotide Therapy Based Drug Market Porter's Five Forces Analysis
- 5.6.1 Global Trade Frictions
- 5.6.2 U.S. Tariff Policy – April 2025
- 5.6.3 Global Trade Frictions and Their Impacts to Oligonucleotide Therapy Based Drug Market
- 5.7 ESG Ratings of Leading Companies
- 6 Oligonucleotide Therapy Based Drug Market Segmentation by Type
- 6.1 Evaluation Matrix of Segment Market Development Potential (Type)
- 6.2 Global Oligonucleotide Therapy Based Drug Sales Market Share by Type (2020-2025)
- 6.3 Global Oligonucleotide Therapy Based Drug Market Size Market Share by Type (2020-2025)
- 6.4 Global Oligonucleotide Therapy Based Drug Price by Type (2020-2025)
- 7 Oligonucleotide Therapy Based Drug Market Segmentation by Application
- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Oligonucleotide Therapy Based Drug Market Sales by Application (2020-2025)
- 7.3 Global Oligonucleotide Therapy Based Drug Market Size (M USD) by Application (2020-2025)
- 7.4 Global Oligonucleotide Therapy Based Drug Sales Growth Rate by Application (2020-2025)
- 8 Oligonucleotide Therapy Based Drug Market Sales by Region
- 8.1 Global Oligonucleotide Therapy Based Drug Sales by Region
- 8.1.1 Global Oligonucleotide Therapy Based Drug Sales by Region
- 8.1.2 Global Oligonucleotide Therapy Based Drug Sales Market Share by Region
- 8.2 Global Oligonucleotide Therapy Based Drug Market Size by Region
- 8.2.1 Global Oligonucleotide Therapy Based Drug Market Size by Region
- 8.2.2 Global Oligonucleotide Therapy Based Drug Market Size Market Share by Region
- 8.3 North America
- 8.3.1 North America Oligonucleotide Therapy Based Drug Sales by Country
- 8.3.2 North America Oligonucleotide Therapy Based Drug Market Size by Country
- 8.3.3 U.S. Market Overview
- 8.3.4 Canada Market Overview
- 8.3.5 Mexico Market Overview
- 8.4 Europe
- 8.4.1 Europe Oligonucleotide Therapy Based Drug Sales by Country
- 8.4.2 Europe Oligonucleotide Therapy Based Drug Market Size by Country
- 8.4.3 Germany Market Overview
- 8.4.4 France Market Overview
- 8.4.5 U.K. Market Overview
- 8.4.6 Italy Market Overview
- 8.4.7 Spain Market Overview
- 8.5 Asia Pacific
- 8.5.1 Asia Pacific Oligonucleotide Therapy Based Drug Sales by Region
- 8.5.2 Asia Pacific Oligonucleotide Therapy Based Drug Market Size by Region
- 8.5.3 China Market Overview
- 8.5.4 Japan Market Overview
- 8.5.5 South Korea Market Overview
- 8.5.6 India Market Overview
- 8.5.7 Southeast Asia Market Overview
- 8.6 South America
- 8.6.1 South America Oligonucleotide Therapy Based Drug Sales by Country
- 8.6.2 South America Oligonucleotide Therapy Based Drug Market Size by Country
- 8.6.3 Brazil Market Overview
- 8.6.4 Argentina Market Overview
- 8.6.5 Columbia Market Overview
- 8.7 Middle East and Africa
- 8.7.1 Middle East and Africa Oligonucleotide Therapy Based Drug Sales by Region
- 8.7.2 Middle East and Africa Oligonucleotide Therapy Based Drug Market Size by Region
- 8.7.3 Saudi Arabia Market Overview
- 8.7.4 UAE Market Overview
- 8.7.5 Egypt Market Overview
- 8.7.6 Nigeria Market Overview
- 8.7.7 South Africa Market Overview
- 9 Oligonucleotide Therapy Based Drug Market Production by Region
- 9.1 Global Production of Oligonucleotide Therapy Based Drug by Region(2020-2025)
- 9.2 Global Oligonucleotide Therapy Based Drug Revenue Market Share by Region (2020-2025)
- 9.3 Global Oligonucleotide Therapy Based Drug Production, Revenue, Price and Gross Margin (2020-2025)
- 9.4 North America Oligonucleotide Therapy Based Drug Production
- 9.4.1 North America Oligonucleotide Therapy Based Drug Production Growth Rate (2020-2025)
- 9.4.2 North America Oligonucleotide Therapy Based Drug Production, Revenue, Price and Gross Margin (2020-2025)
- 9.5 Europe Oligonucleotide Therapy Based Drug Production
- 9.5.1 Europe Oligonucleotide Therapy Based Drug Production Growth Rate (2020-2025)
- 9.5.2 Europe Oligonucleotide Therapy Based Drug Production, Revenue, Price and Gross Margin (2020-2025)
- 9.6 Japan Oligonucleotide Therapy Based Drug Production (2020-2025)
- 9.6.1 Japan Oligonucleotide Therapy Based Drug Production Growth Rate (2020-2025)
- 9.6.2 Japan Oligonucleotide Therapy Based Drug Production, Revenue, Price and Gross Margin (2020-2025)
- 9.7 China Oligonucleotide Therapy Based Drug Production (2020-2025)
- 9.7.1 China Oligonucleotide Therapy Based Drug Production Growth Rate (2020-2025)
- 9.7.2 China Oligonucleotide Therapy Based Drug Production, Revenue, Price and Gross Margin (2020-2025)
- 10 Key Companies Profile
- 10.1 Sarepta Therapeutics_x000D_
- 10.1.1 Sarepta Therapeutics_x000D_ Basic Information
- 10.1.2 Sarepta Therapeutics_x000D_ Oligonucleotide Therapy Based Drug Product Overview
- 10.1.3 Sarepta Therapeutics_x000D_ Oligonucleotide Therapy Based Drug Product Market Performance
- 10.1.4 Sarepta Therapeutics_x000D_ Business Overview
- 10.1.5 Sarepta Therapeutics_x000D_ SWOT Analysis
- 10.1.6 Sarepta Therapeutics_x000D_ Recent Developments
- 10.2 Ionis Pharmaceuticals_x000D_
- 10.2.1 Ionis Pharmaceuticals_x000D_ Basic Information
- 10.2.2 Ionis Pharmaceuticals_x000D_ Oligonucleotide Therapy Based Drug Product Overview
- 10.2.3 Ionis Pharmaceuticals_x000D_ Oligonucleotide Therapy Based Drug Product Market Performance
- 10.2.4 Ionis Pharmaceuticals_x000D_ Business Overview
- 10.2.5 Ionis Pharmaceuticals_x000D_ SWOT Analysis
- 10.2.6 Ionis Pharmaceuticals_x000D_ Recent Developments
- 10.3 Alnylam_x000D_
- 10.3.1 Alnylam_x000D_ Basic Information
- 10.3.2 Alnylam_x000D_ Oligonucleotide Therapy Based Drug Product Overview
- 10.3.3 Alnylam_x000D_ Oligonucleotide Therapy Based Drug Product Market Performance
- 10.3.4 Alnylam_x000D_ Business Overview
- 10.3.5 Alnylam_x000D_ SWOT Analysis
- 10.3.6 Alnylam_x000D_ Recent Developments
- 10.4 Biogen_x000D_
- 10.4.1 Biogen_x000D_ Basic Information
- 10.4.2 Biogen_x000D_ Oligonucleotide Therapy Based Drug Product Overview
- 10.4.3 Biogen_x000D_ Oligonucleotide Therapy Based Drug Product Market Performance
- 10.4.4 Biogen_x000D_ Business Overview
- 10.4.5 Biogen_x000D_ Recent Developments
- 10.5 Nippon Shinyaku_x000D_
- 10.5.1 Nippon Shinyaku_x000D_ Basic Information
- 10.5.2 Nippon Shinyaku_x000D_ Oligonucleotide Therapy Based Drug Product Overview
- 10.5.3 Nippon Shinyaku_x000D_ Oligonucleotide Therapy Based Drug Product Market Performance
- 10.5.4 Nippon Shinyaku_x000D_ Business Overview
- 10.5.5 Nippon Shinyaku_x000D_ Recent Developments
- 10.6 Sobi_x000D_
- 10.6.1 Sobi_x000D_ Basic Information
- 10.6.2 Sobi_x000D_ Oligonucleotide Therapy Based Drug Product Overview
- 10.6.3 Sobi_x000D_ Oligonucleotide Therapy Based Drug Product Market Performance
- 10.6.4 Sobi_x000D_ Business Overview
- 10.6.5 Sobi_x000D_ Recent Developments
- 10.7 Novartis_x000D_
- 10.7.1 Novartis_x000D_ Basic Information
- 10.7.2 Novartis_x000D_ Oligonucleotide Therapy Based Drug Product Overview
- 10.7.3 Novartis_x000D_ Oligonucleotide Therapy Based Drug Product Market Performance
- 10.7.4 Novartis_x000D_ Business Overview
- 10.7.5 Novartis_x000D_ Recent Developments
- 10.8 BioNTech_x000D_
- 10.8.1 BioNTech_x000D_ Basic Information
- 10.8.2 BioNTech_x000D_ Oligonucleotide Therapy Based Drug Product Overview
- 10.8.3 BioNTech_x000D_ Oligonucleotide Therapy Based Drug Product Market Performance
- 10.8.4 BioNTech_x000D_ Business Overview
- 10.8.5 BioNTech_x000D_ Recent Developments
- 10.9 Pfizer_x000D_
- 10.9.1 Pfizer_x000D_ Basic Information
- 10.9.2 Pfizer_x000D_ Oligonucleotide Therapy Based Drug Product Overview
- 10.9.3 Pfizer_x000D_ Oligonucleotide Therapy Based Drug Product Market Performance
- 10.9.4 Pfizer_x000D_ Business Overview
- 10.9.5 Pfizer_x000D_ Recent Developments
- 10.10 Moderna Therapeutics_x000D_
- 10.10.1 Moderna Therapeutics_x000D_ Basic Information
- 10.10.2 Moderna Therapeutics_x000D_ Oligonucleotide Therapy Based Drug Product Overview
- 10.10.3 Moderna Therapeutics_x000D_ Oligonucleotide Therapy Based Drug Product Market Performance
- 10.10.4 Moderna Therapeutics_x000D_ Business Overview
- 10.10.5 Moderna Therapeutics_x000D_ Recent Developments
- 10.11 Jazz Pharmaceuticals_x000D_
- 10.11.1 Jazz Pharmaceuticals_x000D_ Basic Information
- 10.11.2 Jazz Pharmaceuticals_x000D_ Oligonucleotide Therapy Based Drug Product Overview
- 10.11.3 Jazz Pharmaceuticals_x000D_ Oligonucleotide Therapy Based Drug Product Market Performance
- 10.11.4 Jazz Pharmaceuticals_x000D_ Business Overview
- 10.11.5 Jazz Pharmaceuticals_x000D_ Recent Developments
- 10.12 CureVac_x000D_
- 10.12.1 CureVac_x000D_ Basic Information
- 10.12.2 CureVac_x000D_ Oligonucleotide Therapy Based Drug Product Overview
- 10.12.3 CureVac_x000D_ Oligonucleotide Therapy Based Drug Product Market Performance
- 10.12.4 CureVac_x000D_ Business Overview
- 10.12.5 CureVac_x000D_ Recent Developments
- 10.13 Regulus Therapeutics_x000D_
- 10.13.1 Regulus Therapeutics_x000D_ Basic Information
- 10.13.2 Regulus Therapeutics_x000D_ Oligonucleotide Therapy Based Drug Product Overview
- 10.13.3 Regulus Therapeutics_x000D_ Oligonucleotide Therapy Based Drug Product Market Performance
- 10.13.4 Regulus Therapeutics_x000D_ Business Overview
- 10.13.5 Regulus Therapeutics_x000D_ Recent Developments
- 10.14 ProQR_x000D_
- 10.14.1 ProQR_x000D_ Basic Information
- 10.14.2 ProQR_x000D_ Oligonucleotide Therapy Based Drug Product Overview
- 10.14.3 ProQR_x000D_ Oligonucleotide Therapy Based Drug Product Market Performance
- 10.14.4 ProQR_x000D_ Business Overview
- 10.14.5 ProQR_x000D_ Recent Developments
- 10.15 Secarna_x000D_
- 10.15.1 Secarna_x000D_ Basic Information
- 10.15.2 Secarna_x000D_ Oligonucleotide Therapy Based Drug Product Overview
- 10.15.3 Secarna_x000D_ Oligonucleotide Therapy Based Drug Product Market Performance
- 10.15.4 Secarna_x000D_ Business Overview
- 10.15.5 Secarna_x000D_ Recent Developments
- 10.16 MiNA Therapeutics_x000D_
- 10.16.1 MiNA Therapeutics_x000D_ Basic Information
- 10.16.2 MiNA Therapeutics_x000D_ Oligonucleotide Therapy Based Drug Product Overview
- 10.16.3 MiNA Therapeutics_x000D_ Oligonucleotide Therapy Based Drug Product Market Performance
- 10.16.4 MiNA Therapeutics_x000D_ Business Overview
- 10.16.5 MiNA Therapeutics_x000D_ Recent Developments
- 10.17 Sylentis_x000D_
- 10.17.1 Sylentis_x000D_ Basic Information
- 10.17.2 Sylentis_x000D_ Oligonucleotide Therapy Based Drug Product Overview
- 10.17.3 Sylentis_x000D_ Oligonucleotide Therapy Based Drug Product Market Performance
- 10.17.4 Sylentis_x000D_ Business Overview
- 10.17.5 Sylentis_x000D_ Recent Developments
- 10.18 Arrowhead_x000D_
- 10.18.1 Arrowhead_x000D_ Basic Information
- 10.18.2 Arrowhead_x000D_ Oligonucleotide Therapy Based Drug Product Overview
- 10.18.3 Arrowhead_x000D_ Oligonucleotide Therapy Based Drug Product Market Performance
- 10.18.4 Arrowhead_x000D_ Business Overview
- 10.18.5 Arrowhead_x000D_ Recent Developments
- 10.19 Silence Therapeutics_x000D_
- 10.19.1 Silence Therapeutics_x000D_ Basic Information
- 10.19.2 Silence Therapeutics_x000D_ Oligonucleotide Therapy Based Drug Product Overview
- 10.19.3 Silence Therapeutics_x000D_ Oligonucleotide Therapy Based Drug Product Market Performance
- 10.19.4 Silence Therapeutics_x000D_ Business Overview
- 10.19.5 Silence Therapeutics_x000D_ Recent Developments
- 10.20 Dicerna
- 10.20.1 Dicerna Basic Information
- 10.20.2 Dicerna Oligonucleotide Therapy Based Drug Product Overview
- 10.20.3 Dicerna Oligonucleotide Therapy Based Drug Product Market Performance
- 10.20.4 Dicerna Business Overview
- 10.20.5 Dicerna Recent Developments
- 11 Oligonucleotide Therapy Based Drug Market Forecast by Region
- 11.1 Global Oligonucleotide Therapy Based Drug Market Size Forecast
- 11.2 Global Oligonucleotide Therapy Based Drug Market Forecast by Region
- 11.2.1 North America Market Size Forecast by Country
- 11.2.2 Europe Oligonucleotide Therapy Based Drug Market Size Forecast by Country
- 11.2.3 Asia Pacific Oligonucleotide Therapy Based Drug Market Size Forecast by Region
- 11.2.4 South America Oligonucleotide Therapy Based Drug Market Size Forecast by Country
- 11.2.5 Middle East and Africa Forecasted Sales of Oligonucleotide Therapy Based Drug by Country
- 12 Forecast Market by Type and by Application (2026-2033)
- 12.1 Global Oligonucleotide Therapy Based Drug Market Forecast by Type (2026-2033)
- 12.1.1 Global Forecasted Sales of Oligonucleotide Therapy Based Drug by Type (2026-2033)
- 12.1.2 Global Oligonucleotide Therapy Based Drug Market Size Forecast by Type (2026-2033)
- 12.1.3 Global Forecasted Price of Oligonucleotide Therapy Based Drug by Type (2026-2033)
- 12.2 Global Oligonucleotide Therapy Based Drug Market Forecast by Application (2026-2033)
- 12.2.1 Global Oligonucleotide Therapy Based Drug Sales (K MT) Forecast by Application
- 12.2.2 Global Oligonucleotide Therapy Based Drug Market Size (M USD) Forecast by Application (2026-2033)
- 13 Conclusion and Key Findings
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
